about
Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic ReviewBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerThe minority report: targeting the rare oncogenes in NSCLCComparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsCrizotinib in ROS1-rearranged non-small-cell lung cancer.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Testing for ROS1 in non-small cell lung cancer: a review with recommendationsAn Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscapeFluorescence in situ hybridization in surgical pathology: principles and applications.Molecular pathways and therapeutic targets in lung cancerTargeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerActivation of RAS family members confers resistance to ROS1 targeting drugs.Recent advances in personalized lung cancer medicineMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondHigh level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis.Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinomaCytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma.Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation.Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerCase report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancerAnalyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.ROS1 copy number alterations are frequent in non-small cell lung cancer.Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.Molecular Testing for Gastrointestinal Cancer.Detecting and targetting oncogenic fusion proteins in the genomic era.Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Current and future molecular diagnostics in non-small-cell lung cancer.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
P2860
Q26825594-593E26A3-A484-4D5F-86D5-3F0A01F4A5C7Q26851421-86AA7CB4-FCB9-4051-9A8E-A5E3723A64CFQ26851636-6132CB6D-4F2D-4FD0-BF04-0F93A6305838Q27311389-3DD3DF3B-C711-4D4E-87C8-50D3B51B617AQ27852601-5E95F997-C2BD-4B76-B04C-C0C3E045E7EEQ27852699-1CA2E640-F06C-4FF7-BFEB-A161F0E0DBE2Q27853012-56059613-519F-450C-94D8-A9103251DA74Q27853075-F11615FB-F5AE-4955-B5DF-5709FB613E87Q27853214-3EC91057-9925-48C9-ADE8-446A0BF76699Q28070062-2B1805F1-9FBD-444B-91A3-CDD72109F8F9Q28265615-67643487-45CD-49AF-A2A2-CB7381640759Q28540825-6F14BFC0-E229-49AC-A347-3C80B542E959Q33593910-6057FFF3-D467-42FE-9B91-2C9B71C209F4Q33688872-1BFE14BD-D9D9-4D8D-98FB-48B74763087CQ34158153-69413853-8D51-41CB-9255-E770DB781A9EQ34392733-9B01BDA1-CEBD-435E-A571-78232A434A47Q34463388-FA8EB51A-6750-4D68-92FB-802C4D284A5BQ34678073-C57E17D7-8E73-4FC6-9AA6-5731F35B8D89Q35136424-7BCE4F82-135B-4702-8C15-2F89AD813A36Q35256622-58FEF783-B640-453F-9AE9-E8EE3C8822C1Q35775228-8A87236A-494F-460B-B9F3-C53FE9161D88Q35790161-8BED6681-79A6-4CA5-A43A-5281D7190BA0Q35811132-2CC7654C-1858-4ABB-8F02-BF971B073BC8Q35871442-338E1BB1-1C11-4346-A96D-5151EF141D66Q35999416-22E0FAB0-1E15-4582-A4FE-0AEF555D37A6Q36136571-9FDE7D6D-A07F-46BE-B741-67F40DF7EF2AQ36260477-A73C36F3-D569-4EBF-BEF9-FA3C3C4BA7AFQ36276051-2EDFE4AE-9F6F-4267-8B0C-9A8FCF4A00ADQ36629689-CC31E6DD-6583-4F91-9A5F-B912854B2993Q36891466-5AADABF3-2CDD-4566-94A3-08A80C85CC68Q36946705-FA21E292-AE28-477C-AEE1-D0C062E9D52CQ37162291-43A733F1-20BC-4C99-9E87-0D28AEF3EAD8Q37373037-B93EBE5A-9333-425C-B809-009699D097E8Q37687285-ABD3797A-584B-4311-8853-9FD64F300F3BQ37710556-B3B01455-CF3E-49EE-84CD-C64F2EBEAB01Q38336067-3E5E3C9B-7E85-4AAA-851E-93D07857ECFDQ38386866-4ED32985-8C1C-4B61-98F9-359E251DCC14Q38390200-6C53D10C-16F7-43A1-A6C4-4F612F3E6D88Q38543780-5A2FC526-4928-4B2D-BB61-4E61C6BF1C7DQ38584814-696EB567-A796-450D-971C-E34B42794126
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Molecular pathways: ROS1 fusion proteins in cancer.
@ast
Molecular pathways: ROS1 fusion proteins in cancer.
@en
Molecular pathways: ROS1 fusion proteins in cancer.
@nl
type
label
Molecular pathways: ROS1 fusion proteins in cancer.
@ast
Molecular pathways: ROS1 fusion proteins in cancer.
@en
Molecular pathways: ROS1 fusion proteins in cancer.
@nl
prefLabel
Molecular pathways: ROS1 fusion proteins in cancer.
@ast
Molecular pathways: ROS1 fusion proteins in cancer.
@en
Molecular pathways: ROS1 fusion proteins in cancer.
@nl
P2860
P1476
Molecular pathways: ROS1 fusion proteins in cancer.
@en
P2093
Kurtis D Davies
Robert C Doebele
P2860
P304
P356
10.1158/1078-0432.CCR-12-2851
P407
P577
2013-05-29T00:00:00Z